Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia

Table 2 Brief psychiatric rating scale: Total score and 5-factor model scores from the baseline to 12 weeks after initiation of blonanserin treatment (mean ± SD)

BPRS	Baseline (n = 3306)	2-4 weeks (n = 3188)	6-8 weeks (n = 2957)	12 weeks (n = 2775)	F value	P value
Total score	48.8 ± 15.03	38.5 ± 13.32	32.3 ± 11.78	27.7 ± 10.08	1574	< 0.001
Anxiety/depression	9.8 ± 4.11	8.2 ± 3.46	7.1 ± 3.07	6.2 ± 2.67	638.5	< 0.001
Anergia	10.2 ± 3.69	8.4 ± 3.14	7.2 ± 2.74	6.3 ± 2.38	898.3	< 0.001
Thought disturbance	12.1 ± 4.30	9.4 ± 3.80	7.6 ± 3.33	6.4 ± 2.85	1410	< 0.001
Activation	6.7 ± 3.26	5.3 ± 2.61	4.5 ± 2.17	4.0 ± 1.74	695.5	< 0.001
Hostility/suspiciousness	10.0 ± 3.89	7.3 ± 3.17	5.8 ± 2.63	4.8 ± 2.16	1700	< 0.001

BPRS: Brief psychiatric rating scale.